The global varicella live vaccine market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The zoster virus is also known as human alphaherpesvirus 3 which is responsible for causing chickenpox and herpes zoster in the human body. Since the infection which is caused by these viruses is preventable by using vaccines specially formulated to provide immunity against the virus; the market is anticipated to grow substantially in the future years. By large, there are mainly two types of vaccinates available that provide immunity against varicella zoster. These include monovalent varicella vaccine and combination varicella vaccine. Both these vaccinations vary from each other based on their composition. For instance, the monovalent varicella vaccine has only one strain of virus whereas the combination varicella vaccine contains more than one strain of the virus and offers immunity against more than one virus. Based on their specific utility, both these vaccines are administered to the human body.

The market is segmented on the basis of application, product, provider. On the basis of product, the market is bifurcated into monovalent varicella vaccine and combination varicella vaccine. Among these, the combination varicella vaccine sub-segment is anticipated to register a substantial growth owing to its ability to introduce more than one strain of virus while also offering immunity against more than one virus. Further, on the basis of application, the market is divided into chickenpox immunization, herpes zoster immunization, and measles, mumps, rubella, and varicella (MMRV) immunization. Among the application segment, the chickenpox immunization segment is likely to hold a prominent market share. The immunization for these vaccines is quite high in the emerging economies of Asia-Pacific such as India.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  GlaxoSmithKline plc, Merck & Co., Inc., and Sanofi SA, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Varicella Live Vaccine Market Report by Segment

By Type

• Monovalent Vaccine 
• Combination Vaccine

By Application

• Chickenpox Immunization 
• Herpes Zoster Immunization
• MMRV Immunization

Global Varicella Live Vaccine Market by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa